Answers are grounded in this paper and cite their sources.
There are no clinically meaningful differences in steady-state PK or PD between ertugliflozin BID and QD regimens at total daily doses of 5 and 15 mg, supporting BID administration of ertugliflozin as a component of the ertugliflozin/metformin (immediate-release) FDC.
No takes yet. Share an insight, caveat, or question.
Dawra et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: